Suppr超能文献

肾性尿崩症:三十年临床实况

Nephrogenic Diabetes Insipidus: Three Decades of Clinical Reality.

作者信息

Gouveia Lopes Mariana, Peixoto Daniela T, Neves Catarina, Machado Marta, Cordinhã Carolina, Carmo Carmen, Gomes Clara

机构信息

Pediatrics, Unidade Local de Saúde da Região de Leiria, Leiria, PRT.

Pediatrics, Unidade Local de Saúde da Região de Aveiro, Aveiro, PRT.

出版信息

Cureus. 2025 Aug 8;17(8):e89635. doi: 10.7759/cureus.89635. eCollection 2025 Aug.

Abstract

Introduction Nephrogenic diabetes insipidus (NDI) is a rare condition caused by renal resistance to the action of antidiuretic hormone (ADH) at the level of the distal tubule, resulting in impaired urinary concentration and consequent polyuria. NDI may be hereditary, most commonly X-linked due to AVPR2 gene mutations, or acquired. Objective To characterize the clinical features, management strategies, and outcomes of patients with NDI followed at a tertiary pediatric nephrology center. Methods A retrospective observational study was conducted, including pediatric patients diagnosed with NDI between 1991 and 2024. Data regarding clinical presentation, diagnostic approach, management strategies, and long-term outcomes were collected and analyzed. Results Eight patients (including one set of twins) were identified; seven (87.5%) were male subjects. The median age at diagnosis was 7.5 months (interquartile range (IQR): 6.0-9.0). All patients presented with polydipsia, polyuria (median diuresis: 10.0 (IQR: 9.0-10.2) mL/kg/h), and failure to thrive. Constipation and recurrent fever were observed in two patients (25.0%). At diagnosis, the median serum sodium level was 160.5 mmol/L (IQR: 139-168), and the urine/plasma osmolality ratio was 0.41 (IQR: 0.26-0.49). No patients exhibited metabolic acidosis. All desmopressin tests were negative. Genetic testing was performed in four patients, all of whom had pathogenic X-linked AVPR2 variants. All patients were treated with hydrochlorothiazide and amiloride; indomethacin was added in 5 (62.5%). Serum sodium normalized in all cases. Over a median follow-up period of 16.9 years (IQR: 8.4-17.4), growth improved, but all patients continued to exhibit polyuria and polydipsia. Neurodevelopmental disorders were identified in six patients, including intellectual disability, autism spectrum disorder, language delay, and learning difficulties. Renal function, serum sodium, and imaging findings remained stable throughout follow-up. At the final assessment, all patients remained on hydrochlorothiazide and amiloride. Five transitioned to adult nephrology at a median age of 17.0 years (IQR: 16.0-17.0). Conclusion Although rare, NDI can significantly impact growth and neurodevelopment. The diagnosis should be considered in infants with failure to thrive, especially when accompanied by polyuria and polydipsia. Early recognition and intervention, even if non-specific, may improve long-term outcomes.

摘要

引言

肾性尿崩症(NDI)是一种罕见疾病,由远端肾小管对抗利尿激素(ADH)作用产生抵抗所致,导致尿液浓缩功能受损,进而引起多尿。NDI 可能是遗传性的,最常见的是因 AVPR2 基因突变导致的 X 连锁遗传,也可能是后天获得性的。

目的

描述在一家三级儿科肾脏病中心随访的 NDI 患者的临床特征、管理策略及预后。

方法

进行了一项回顾性观察研究,纳入 1991 年至 2024 年间诊断为 NDI 的儿科患者。收集并分析了有关临床表现、诊断方法、管理策略及长期预后的数据。

结果

共确定了 8 例患者(包括一对双胞胎);7 例(87.5%)为男性。诊断时的中位年龄为 7.5 个月(四分位间距(IQR):6.0 - 9.0)。所有患者均有多饮、多尿(中位尿量:10.0(IQR:9.0 - 10.2)mL/kg/h)及生长发育迟缓。2 例患者(25.0%)出现便秘和反复发热。诊断时,中位血清钠水平为 160.5 mmol/L(IQR:139 - 168),尿/血浆渗透压比值为 0.41(IQR:0.26 - 0.49)。无患者出现代谢性酸中毒。所有去氨加压素试验均为阴性。对 4 例患者进行了基因检测,所有患者均有致病性 X 连锁 AVPR2 变异。所有患者均接受氢氯噻嗪和阿米洛利治疗;5 例(62.5%)加用了吲哚美辛。所有病例血清钠均恢复正常。在中位随访期 16.9 年(IQR:8.4 - 17.4)内,生长情况有所改善,但所有患者仍有多尿和多饮症状。6 例患者被发现有神经发育障碍,包括智力残疾、自闭症谱系障碍、语言发育迟缓及学习困难。随访期间肾功能、血清钠及影像学检查结果保持稳定。在最后评估时,所有患者仍在服用氢氯噻嗪和阿米洛利。5 例患者在中位年龄 17.0 岁(IQR:16.0 - 17.0)时转诊至成人肾脏病科。

结论

尽管 NDI 罕见,但可显著影响生长发育和神经发育。对于生长发育迟缓的婴儿,尤其是伴有多尿和多饮时,应考虑该诊断。早期识别和干预,即使是非特异性的,也可能改善长期预后。

本文引用的文献

2
Genetic basis of nephrogenic diabetes insipidus.
Mol Cell Endocrinol. 2023 Jan 15;560:111825. doi: 10.1016/j.mce.2022.111825. Epub 2022 Nov 30.
3
Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group for Renaming Diabetes Insipidus.
J Clin Endocrinol Metab. 2022 Dec 17;108(1):1-3. doi: 10.1210/clinem/dgac547.
4
Nephrogenic diabetes insipidus in children (Review).
Exp Ther Med. 2021 Jul;22(1):746. doi: 10.3892/etm.2021.10178. Epub 2021 May 11.
5
Diabetes Insipidus: Pathogenesis, Diagnosis, and Clinical Management.
Cureus. 2021 Feb 23;13(2):e13523. doi: 10.7759/cureus.13523.
6
Treatment and long-term outcome in primary nephrogenic diabetes insipidus.
Nephrol Dial Transplant. 2020 Dec 26. doi: 10.1093/ndt/gfaa243.
8
Diabetes Insipidus.
Pediatr Rev. 2020 Feb;41(2):96-99. doi: 10.1542/pir.2018-0337.
9
Nephrogenic Diabetes Insipidus.
Exp Suppl. 2019;111:317-339. doi: 10.1007/978-3-030-25905-1_15.
10
Long-term outcome in inherited nephrogenic diabetes insipidus.
Clin Kidney J. 2018 Apr 13;12(2):180-187. doi: 10.1093/ckj/sfy027. eCollection 2019 Apr.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验